PHARMACOR SITAGLIPTIN sitagliptin 25 mg film-coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor sitagliptin sitagliptin 25 mg film-coated tablet blister pack

pharmacor pty ltd - sitagliptin hydrochloride monohydrate, quantity: 27.25 mg (equivalent: sitagliptin, qty 25 mg) - tablet, film coated - excipient ingredients: magnesium stearate; povidone; croscarmellose sodium; microcrystalline cellulose; sodium stearylfumarate; calcium hydrogen phosphate dihydrate; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black - pharmacor sitagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as:,- monotherapy when metformin is considered inappropriate due to intolerance; or,- in combination with other anti-hyperglycaemic agents, including insulin,[see 5.1 pharmacodynamic properties, clinical trials, 4.5 interactions with other medicines and other forms of interactions for available data on different add-on combination therapies].

PHARMACOR SITAGLIPTIN sitagliptin 25 mg film-coated tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor sitagliptin sitagliptin 25 mg film-coated tablet bottle

pharmacor pty ltd - sitagliptin hydrochloride monohydrate, quantity: 27.25 mg (equivalent: sitagliptin, qty 25 mg) - tablet, film coated - excipient ingredients: sodium stearylfumarate; croscarmellose sodium; povidone; microcrystalline cellulose; calcium hydrogen phosphate dihydrate; magnesium stearate; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black - pharmacor sitagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as:,- monotherapy when metformin is considered inappropriate due to intolerance; or,- in combination with other anti-hyperglycaemic agents, including insulin,[see 5.1 pharmacodynamic properties, clinical trials, 4.5 interactions with other medicines and other forms of interactions for available data on different add-on combination therapies].

PHARMACOR SITAGLIPTIN sitagliptin 100 mg film-coated tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor sitagliptin sitagliptin 100 mg film-coated tablet bottle

pharmacor pty ltd - sitagliptin hydrochloride monohydrate, quantity: 109 mg (equivalent: sitagliptin, qty 100 mg) - tablet, film coated - excipient ingredients: sodium stearylfumarate; magnesium stearate; povidone; croscarmellose sodium; calcium hydrogen phosphate dihydrate; microcrystalline cellulose; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - pharmacor sitagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as:,- monotherapy when metformin is considered inappropriate due to intolerance; or,- in combination with other anti-hyperglycaemic agents, including insulin,[see 5.1 pharmacodynamic properties, clinical trials, 4.5 interactions with other medicines and other forms of interactions for available data on different add-on combination therapies].

Sitagliptin Accord European Union - English - EMA (European Medicines Agency)

sitagliptin accord

accord healthcare s.l.u. - sitagliptin hydrochloride - diabetes mellitus, type 2 - drugs used in diabetes - for adult patients with type 2 diabetes mellitus, sitagliptin accord is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance.as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control.- a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance.- a peroxisome proliferator-activated receptor gamma (ppary) agonist (i.e. a thiazolidinedione) when use of a ppary agonist is appropriate and when diet and exercise plus the ppary agonist alone do not provide adequate glycaemic control.as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.- a ppary agonist and metformin when use of a ppary agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.sitagliptin accord is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

MSD-ERTUGLIFLOZIN-SITAGLIPTIN 15/100 ertugliflozin/sitagliptin (as phosphate monohydrate) 15 mg/100 mg film-coated tablet bliste Australia - English - Department of Health (Therapeutic Goods Administration)

msd-ertugliflozin-sitagliptin 15/100 ertugliflozin/sitagliptin (as phosphate monohydrate) 15 mg/100 mg film-coated tablet bliste

merck sharp & dohme (australia) pty ltd - sitagliptin phosphate monohydrate, quantity: 128.5 mg (equivalent: sitagliptin, qty 100 mg); ertugliflozin pyroglutamic acid, quantity: 19.43 mg (equivalent: ertugliflozin, qty 15 mg) - tablet, film coated - excipient ingredients: magnesium stearate; sodium stearylfumarate; microcrystalline cellulose; croscarmellose sodium; calcium hydrogen phosphate; carnauba wax; titanium dioxide; hypromellose; hyprolose; iron oxide yellow; iron oxide red; iron oxide black - msd-ertugliflozin-sitagliptin (ertugliflozin and sitagliptin phosphate monohydrate) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both ertugliflozin and sitagliptin is appropriate. [see 5.1 pharmacodynamic properties, clinical trials, and 4.4 special warnings and precautions for use]

SITAGLIPTIN-METFORMIN TABLET Canada - English - Health Canada

sitagliptin-metformin tablet

sivem pharmaceuticals ulc - sitagliptin (sitagliptin phosphate monohydrate); metformin hydrochloride - tablet - 50mg; 500mg - sitagliptin (sitagliptin phosphate monohydrate) 50mg; metformin hydrochloride 500mg

SITAGLIPTIN-METFORMIN TABLET Canada - English - Health Canada

sitagliptin-metformin tablet

sivem pharmaceuticals ulc - sitagliptin (sitagliptin phosphate monohydrate); metformin hydrochloride - tablet - 50mg; 850mg - sitagliptin (sitagliptin phosphate monohydrate) 50mg; metformin hydrochloride 850mg

SITAGLIPTIN-METFORMIN TABLET Canada - English - Health Canada

sitagliptin-metformin tablet

sivem pharmaceuticals ulc - sitagliptin (sitagliptin phosphate monohydrate); metformin hydrochloride - tablet - 50mg; 1000mg - sitagliptin (sitagliptin phosphate monohydrate) 50mg; metformin hydrochloride 1000mg

APO-SITAGLIPTIN/METFORMIN XR TABLET (EXTENDED-RELEASE) Canada - English - Health Canada

apo-sitagliptin/metformin xr tablet (extended-release)

apotex inc - sitagliptin (sitagliptin phosphate monohydrate); metformin hydrochloride - tablet (extended-release) - 50mg; 500mg - sitagliptin (sitagliptin phosphate monohydrate) 50mg; metformin hydrochloride 500mg

APO-SITAGLIPTIN/METFORMIN XR TABLET (EXTENDED-RELEASE) Canada - English - Health Canada

apo-sitagliptin/metformin xr tablet (extended-release)

apotex inc - sitagliptin (sitagliptin phosphate monohydrate); metformin hydrochloride - tablet (extended-release) - 50mg; 1000mg - sitagliptin (sitagliptin phosphate monohydrate) 50mg; metformin hydrochloride 1000mg